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RECENTL Y brequinar sodium (BQR), has been de-
scribed as a new immunosuppressive drug that in-
hibits de novo pyrimidine biosynthesis. By inhibiting the 
enzyme dihydroorotate dehydrogenase, BQR abrogates 
both DNA and RNA synthesis during cell proliferation. l In 
addition, we have recently reported that BQR may also 
inhibit the activity of cytidine deaminase, which results in 
the potentiation of BQR's antilymphocytic activity when 
used in combination with cytidine, but not uridine.2 BQR 
has been shown to be an effective immunosuppressive 
drug in preventing rejection of heart, liver. and kidney 
allografts and concordant cardiac xenograft in rats. 3 How-
ever. in contrast to results reported by Cramer et ai, our 
unpublished results showed that the prolongation of car-
diac xenograft survival by BQR in the hamster-to-rat 
model was approximately 4 days, despite the administra-
tion of the same dose of BQR. Based on the potentiation of 
BQR's antilymphocytic effect by cytidine in vitro. we 
attempted to confirm the stronger immunosuppressive 
effect of BQR plus cytidine in this cardiac xenograft 
model. In addition. the effect of administering BQR plus 
cytidine on the serum lymphocytotoxic antibody levels 
was measured. 
As 'shown in Fig la, the mean graft survival time of 
hamster heart grafts was 3 days (n = 6) for the untreated 
controls. Cytidine. at a dose of 73 mg/kg per day, did not 
affect the mean graft survival time (3.4 ± 0.5 days, n = 8). 
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In contrast, BQR, at a dose of 3 mg/kg per day, signifi-
cantly prolonged hamster heart graft survival to 6.8 ± 1.3 
days (n = 12, P < .005 compared with untreated controls). 
When combining BQR 3 mg/kg per day with cytidine 73 
mg/kg per day, hamster heart graft survival was further 
prolonged to 21.4 ± 12.7 days (n = 14, P = .001 compared 
with BQR treated recipients). Among these 14 animals, 3 
recipients died on days 23, 26, and 31 with functioning 
grafts. This result shows that the administration of BQR 
plus cytidine represents a more potent immunosuppressive 
protocol for control of cardiac xenograft rejection. 
As shown in Fig Ib, treatment of cardiac xenograft 
recipients with BQR caused an approximately three-fold 
reduction in cytotoxic antibody level between days 5 and 7 
after transplant. Combination of BQR and cytidine re-
sulted in a further slight reduction in antibody titre, but 
antibody level increased gradually despite continuous 
treatment. 
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Fig 1. (A) Prolongation of cardiac xenograft survival by a combination of BaR and cytidine. (8) Antihamster cytotoxiC antibody titres. 
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